CYP19A1 and breast cancer: Although the agents inhibit peripheral aromatase activity, the relationship between potency in lowering plasma oestrogen levels and clinical effectiveness in treating breast cancer is poorly defined and it has been suggested that effects on circulating oestrogens do not entirely account for anti-tumour influences (Bajetta et al, 1999).